In other words, in EGFR mutant tumors, PD-L1 expression is not the result of an immune process (i.e., upregulation induced by IFN-γ produced as result of an ongoing immune response), but is a mechanism of tumor immune escape. The gene discussed is IFNG; the disease is neoplasm.